Efficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: Low-dose versus high-dose

Basit Öğe Kaydı
dc.contributor.authorKunt, Ayşegül
dc.contributor.authorÖzcan, Sedat
dc.contributor.authorKüçüker, Aslihan
dc.contributor.authorOdabaşi, Dolunay
dc.contributor.authorKunt, Alper Sami
dc.date.accessioned2025-01-27T18:58:50Z
dc.date.available2025-01-27T18:58:50Z
dc.date.issued2015
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractAim To investigate whether chronic statin treatment after coronary artery bypass grafting (CABG) protects patients from major cardiac events and provides percutaneous coronary intervention (PCI) free survival. Methods A total of 232 patients with previous CABG and chronic statin therapy were selected retrospectively and were divided into two groups according to a dosage of atorvastatin per day, e. g., 20 mg or 40 mg. Groups were compared for the major cardiac events and freedom from PCI by Kaplan Meier analysis as the primary end point. Patency of grafts including left internal thoracic artery (LITA) and saphenous vein (SVG) and progression of non-grafted native vessel disease were also evaluated as secondary end points. Results Cardiac mortality, periprocedural myocardial infarction (MI), target vessel revascularization and percutaneous coronary intervention free survival were as follows: 2.9% versus 2.1% (p=1.000); 16.1% versus 21.1% (p=0.331); 56.93% versus 52.63% (p>0.005); 58.4% versus 63.2% (log-rank test; p= 0.347) in atorvastatin 20 mg and atorvastatin 40 mg groups, respectively. However, these results were not statistically significant between two groups (p>0.005). Patency of openness of grafts including LITA and SVG and progression of non-grafted native vessel disease were similar between groups (p=0.112, p=0.779, p=0.379 and p=0.663, respectively). Conclusion Low-dose long-term statin treatment had similar outcomes on major cardiac events and identical rate of freedom from percutaneous coronary intervention after coronary artery bypass grafting compared with high-dose long-term statin treatment. It is better to start from low dose statin treatment after surgical interventions. © 2015, Medical Association of Zenica-Doboj Canton, All rights reserved.
dc.identifier.doi10.17392/795-15
dc.identifier.endpage201
dc.identifier.issn1840-0132
dc.identifier.issue2
dc.identifier.scopus2-s2.0-84954504749
dc.identifier.scopusqualityQ2
dc.identifier.startpage196
dc.identifier.urihttps://doi.org/10.17392/795-15
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13025
dc.identifier.volume12
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherMedical Association of Zenica-Doboj Canton
dc.relation.ispartofMedicinski Glasnik
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20250125
dc.subjectChronic statin treatment; Coronary bypass grafting; Major cardiac events
dc.titleEfficacy of chronic statin therapy on major cardiac events after coronary artery bypass grafting: Low-dose versus high-dose
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu